APMTD is a privately-held medical device company founded by Dr. Henry Lin and Dr. John Gilbert. The company was founded with the mission to advance cutting-edge medical technology into clinical use and to provide patients with best possible medical care. Since its inception in 2011, the company has been developing technologies for cardiovascular diseases including Stroke, Cardiac Arrest, and peripheral vascular diseases, and has made significant progress. In 2017, the company’s clinical partner presented the first-in-human case of the brain selective hypothermia technology and won the Investigator Award at the American Heart Association Scientific Sessions meeting in San Diego, U.S.A. APMTD is rapidly expanding, and have established R&D, clinical, manufacturing, operation, and market development bases in the U.S., Hong Kong, Taiwan, and China. Our China team have developed the know-how on new product registration, clinical support, provincial tendering, reimbursement, hospital product listing and after-sales support. These provide strong support to our new product development and market entry plan for China. APMTD is dedicated to achieving its goals of improving medicine and helping more patients. In 2017, APMTD received institutional funding support led by Panacea Venture. Panacea Venture focus on investments in innovative and transformative early and growth stage healthcare and life sciences companies worldwide.